Features of pathological anatomy of lungs at COVID-19

The research aim is to study the morphological features of COVID-19 in the lungs of patients who died in Moscow from March 20 to June 6, 2020. Methods. Autopsy material of the lungs from 123 deceased (54 women, 69 men) with COVID-19 coronavirus infection (confirmed by PCR) was analyzed, the median age was 71 (30 – 94) years, and the duration of the disease was 14 (3 – 65) days. In all cases, the patient’s medical records and autopsy reports were analyzed. Macro- and microscopic changes in the lungs were evaluated in all the observations. Results. The pathology of the lungs in COVID-19 corresponds to various phases of diffuse alveolar damage (DAD). The exudative phase of DAD was detected in 54 (43.9%), the proliferative phase – in 21 (14.63%), and their combination – in 51 (41.46%) of the deceased. Histological features of different phases of DAD are described. Conclusion. An analysis of autopsy material revealed a mismatch between the duration of the course of the disease and the phase of diffuse alveolar damage. A significant portion of the dead found a combination of exudative and proliferative phases of the disease. Histological signs that indirectly indicate a violation of the coagulation system during COVID-19 are described.

COVID-19, viral interstitial pneumonia, pathology, coagulopathy

1. Lu R., Zhao X., Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395 (10224): 565–574. DOI: 10.1016/s0140-6736(20)30251-8.

2. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int/?gclid=CjwKCAjwi_b3BRAGEiwAemPNU7B2JwU49WIXL-2GzfGG0bPVQqtXIIwdpVJKQ90n84M2W_m2a4dDyRoCMMsQAvD_BwE [Accessed: July 2, 2020].

3. Magro C., Mulvey J.J., Berlin D. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl. Res. 2020; 220: 1–13. DOI: 10.1016/j.trsl.2020.04.007.

4. Liu J., Li S., Liu J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020; 55: 102763. DOI: 10.1016/j.ebiom.2020.102763.

5. Li H., Liu L., Zhang D. et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020; 395 (10235): 1517–1520. DOI: 10.1016/s0140-6736(20)30920-x.

6. Mauad T., Hajjar L.A., Callegari G.D. et al. Lung pathology in fatal novel human influenza A (H1n1) infection. Am. J. Respir. Crit. Care Med. 2010; 181 (1): 72–79. DOI: 10.1164/rccm.200909-1420oc.

7. Duarte-Neto A.N., Monteiro R.A.A., Silva L.F.F et al. Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy. Histopathology. 2020; 77 (2): 186–197. DOI: 10.1111/his.14160.

8. Gralinski L.E., Bankhead A. 3rd , Jeng S. et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio. 2013; 4 (4): e00271-13. DOI: 10.1128/mbio.00271-13.

9. Li K., Wohlford-Lenane C., Perlman S. et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J. Infect. Dis. 2016; 213 (5): 712–722. DOI: 10.1093/infdis/jiv499.

10. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.

11. Carsana L., Sonzogni A., Nasr A. et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect. Dis. [Preprint. Posted: 2020, Jun. 08]. DOI: 10.1016/s14733099(20)30434-5.

12. Chernyaev A.L., Zairat’yants O.V., Kelli E.I. et al. [Pathological anatomy in A/H1N1 influenza]. Arkhiv patalogii. 2010; 72 (3): 3–6 (in Russian).

13. Zhang H., Zhou P., Wei Y. et al. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Ann. Intern. Med. 2020; 72 (9): 629–632. DOI: 10.7326/M20-0533.

14. Luo W., Yu H., Gou J. et al. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints [Preprint. Posted: 2020, Mar. 9]. Available at: https://www.researchgate.net/profile/Weiren_Luo/publication/339939319_Clinical_Pathology_of_Critical_Patient_with_Novel_Coronavirus_Pneumonia_COVID-19_Pulmonary_Fibrosis_and_Vascular_Changes_including_Microthrombosis_Formation/links/5e888de14585150839befe5d/Clinical-Pathology-of-Critical-Patient-with-Novel-Coronavirus-Pneumonia-COVID-19-Pulmonary-Fibrosis-and-VascularChanges-including-Microthrombosis-Formation.pdf

15. Schaller T., Hirschbühl K., Burkhardt K. et al. Postmortem examination of patients with COVID-19. Research letter. JAMA. 2020; 323 (24): 2518. DOI: 10.1001/jama.2020.8907.

16. Lin L., Lu L., Cao W. et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg. Microbes Infect. 2020; 9 (1): 727–732. DOI: 10.1080/22221751.2020.1746199.

17. McGonagle D., O’Donnell J., Sharif K. et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020; 2 (7): e437–445. DOI: 10.1016/S2665-9913(20)30121-1.

18. Bryce C., Grimes Z., Pujadas E. et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. medRxiv [Preprint. Posted: 2020, May 22]. DOI: 10.1101/2020.05.18.20099960.

19. Wichmann D., Sperhake J.-P., Lütgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19. A prospective cohort study. Ann. Intern. Med. 2020; 173 (4): 268–277. DOI: 10.7326/M20-2003.

20. Edler C., Schröder A.S., Aepfelbacher M. et al. Dying with SARS-CoV-2 infection – an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int. J. Legal Med. 2020; 134 (4): 1275–1284. DOI: 10.1007/s00414-02002317-w.

21. Ackermann M., Verleden S.E., Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N. Engl. J. Med. 2020; 383 (2): 120–128. DOI: 10.1056/NEJMoa2015432.

22. Li G., Fox S.E., Summa B. et al. Multiscale 3-dimensional pathology findings of COVID-19 diseased lung using high-resolution cleared tissue microscopy. bioRxiv [Preprint. Posted: 2020, Apr. 20]. DOI: 10.1101/2020.04.11.037473.

23. Tang N., Bai H., Chen X. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020; 18 (5): 1094–1099. DOI:10.1111/jth.14817.

24. Oudkerk M., Büller H.R., Kuijpers D. et al. Diagnosis, prevention, and treatment of thromboembolic complications in Covid-19: report of the national institute for public health of the Netherlands. Radiology. 2020; 297 (1): e216–222. DOI: 10.1148/radiol.2020201629.

25. Giannis D., Ziogas I.A., Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J. Clin. Virol. 2020; 127: 104362. DOI: 10.1016/j.jcv.2020.104362.

26. Li H., Liu L., Zhang D. et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020; 395 (10235): 1517–1520. DOI: 10.1016/S0140-6736(20)30920-X.

27. Kluge S., Janssens U., Welte T. et al. German recommendations for critically ill patients with COVID-19. Medi. Klin. Intensiv. Notfmed. [Preprint. Posted: 2020, Apr. 14]. DOI: 10.1007/s00063-020-00689-w.

28. Colantuoni A., Martini R., Caprari P. et al. COVID-19 sepsisand microcirculation dysfunction. Front. Physiol. 2020; 11: 747. DOI: 10.3389/fphys.2020.00747.

29. Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395 (10234): 1417–1418. DOI: 10.1016/S0140-6736(20)30937-5

30. Menter T., Haslbauer J.D., Nienhold R. et al. Post-mortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020; 77 (2): 198–209. DOI: 10.1111/HIS.14134.

31. Suess C., Hausmann R. Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation. Int. J. Legal Med. 2020; 134 (4): 1285–1290. DOI: 10.1007/s00414-020-02319-8.

32. Kungurova V.V., Khasanyanova S.V. [On the issue of megakaryocytosis in microcirculatory vessels in various types of death (according to forensic histological studies)]. Problemy ehkspertizy v meditsine. 2015; 15 (1–2): 15–17 (in Russian).

33. Belyanin V.L., Rybakova M.G. [Sepsis. Pathology]. St. Petersburg: GUZ GPАB; 2004 (in Russian).

34. Boilard E., Flamand L. The role of the megakaryocyte in immunity has gone viral. Blood. 2019; 133 (19): 2001–2002. DOI: 10.1182/blood-2019-02-900787.

35. Zabozlaev F.G., Kravchenko E.V., Gallyamova А.R. et al. [Pathological anatomy of the lungs in the new coronavirus infection (COVID-19)]. Klinicheskaya praktika. 2020; 11 (2): 60–76. DOI: 10.17816/clinpract34849 (in Russian).

36. Teoh K.T., Siu Y.L., Chan W.L. et al. The SARS coronavirus E protein interacts with Pals1 and alters tight junction formation and epithelial morphogenesis. Mol. Biol. Cell. 2010; 21 (22): 3838–3852. DOI: 10.1091/mbc.e10-04-0338.

37. Chan E.D., Morales D.V., Welsh C.H. et al. Calcium deposition with or without bone formation in the lung. Am. J. Respir. Crit. Care Med. 2002; 165 (12): 1654–1669. DOI:10.1164/rccm.2108054.

38. Zayratyants O.V., Samsonova M.V., Mikhaleva L.M. et al. [Pathology of COVID-19: Atlas]. Moscow: GBU “NIIOZMM DZM”; 2020 (in Russian).